ASTHMA

Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma

E J Hothersall¹, R Chaudhuri¹, C McSharry², I Donnelly², J Lafferty¹, A D McMahon³, C J Weir³, J Meiklejohn¹, N Sattar⁴, I McInnes⁵, S Wood⁶, N C Thomson¹

¹ Respiratory Medicine, University of Glasgow, Glasgow, UK
² Immunology, University of Glasgow, Glasgow, UK
³ Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK
⁴ Vascular Biochemistry, University of Glasgow, Glasgow, UK
⁵ Rheumatology, University of Glasgow, Glasgow, UK
⁶ General Practice, University of Glasgow, Glasgow, UK

Professor N C Thomson, Respiratory Medicine Section, Division of Immunology, Infection and Inflammation, University of Glasgow and Gartnavel General Hospital, Glasgow G12 0YN, UK; n.c.thomson{at}clinmed.gla.ac.uk

Background: Statins have anti-inflammatory properties that may be beneficial in the treatment of asthma. A study was undertaken to test the hypothesis that atorvastatin added to inhaled corticosteroids improves lung function and airway inflammation in atopic adults with asthma.

Methods: 54 adults with atopic asthma were recruited to a double-blind randomised controlled crossover trial comparing the effect of oral atorvastatin 40 mg daily with that of a matched placebo on asthma control and airway inflammation. Each treatment was administered for 8 weeks separated by a 6-week washout period. The primary outcome was morning peak expiratory flow (PEF). Secondary outcomes included forced expiratory volume in 1 s, asthma control questionnaire score, airway hyper-responsiveness to methacholine, induced sputum cytology and inflammatory biomarkers.

Results: At 8 weeks the change in mean morning PEF compared with baseline did not differ substantially between the atorvastatin and placebo treatment periods (mean difference –0.5 l/min, 95% CI –10.6 to 9.6, p = 0.921). Values for other clinical outcomes were similar between the atorvastatin and placebo treatment periods. The absolute sputum macrophage count was reduced after atorvastatin compared with placebo (mean difference –45.0x10⁴ cells, 95% CI –80.1 to –9.7, p = 0.029), as was the sputum fluid leucotriene B4 (mean difference –88.1 pg/ml, 95% CI –156.4 to –19.9, p = 0.014).

Conclusion: The addition of atorvastatin to inhaled corticosteroids results in no short-term improvement in asthma control but reduces sputum macrophage counts in mild to moderate atopic asthma. The change in sputum macrophage count suggests potential areas for investigation of statins in other chronic lung diseases.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Airwaves

Wisia Wedzicha
Thorax 2008 63: i. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Chiba, Y., Sato, S., Hanazaki, M., Sakai, H., Misawa, M. (2009). Inhibition of geranylgeranyltransferase inhibits bronchial smooth muscle hyperresponsiveness in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 297: L984-L991 [Abstract] [Full Text]  
• Zeki, A. A., Franzi, L., Last, J., Kenyon, N. J. (2009). Simvastatin Inhibits Airway Hyperreactivity: Implications for the Mevalonate Pathway and Beyond. Am. J. Respir. Crit. Care Med. 180: 731-740 [Abstract] [Full Text]  
• Rubin, B. K (2009). Statins for the treatment of asthma: a discovery well, dry hole or just snake oil. Thorax 64: 4-5 [Full Text]